Stocks and Investing
Stocks and Investing
Tue, March 28, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, March 27, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Hartaj Singh Maintained (VIRX) at Buy with Increased Target to $16 on, Mar 27th, 2023
Hartaj Singh of Oppenheimer, Maintained "Viracta Therapeutics, Inc." (VIRX) at Buy with Increased Target from $14 to $16 on, Mar 27th, 2023.
Hartaj has made no other calls on VIRX in the last 4 months.
There are 2 other peers that have a rating on VIRX. Out of the 2 peers that are also analyzing VIRX, 0 agree with Hartaj's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Hartaj
- Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $8 on, Tuesday, March 14th, 2023
- Robert Burns of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $35 on, Tuesday, March 14th, 2023
Contributing Sources